About Epigeneres
Epigeneres is a company based in Mumbai (India) founded in 2008. Epigeneres has raised $9.83 million across 3 funding rounds from investors including HCG, Kotak Mahindra Bank and Torrent Pharma. The company has 76 employees as of April 09, 2024. Epigeneres operates in a competitive market with competitors including GRAIL, Color, Earli, Biovica and RainDance, among others.
- Headquarter Mumbai, India
- Employees 76 as on 09 Apr, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Epigeneres Biotech Private Limited
- Date of Incorporation 25 Apr, 2012
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$419.39 K (USD)3746.86as on Mar 31, 2023
-
Net Profit
-$1.14 M (USD)-716.19as on Mar 31, 2023
-
EBITDA
-$1.22 M (USD)-731.4as on Mar 31, 2023
-
Total Equity Funding
$9.83 M (USD)
in 3 rounds
-
Latest Funding Round
$1.98 M (USD), Series B
Jun 18, 2024
-
Investors
HCG
& 38 more
-
Employee Count
76
as on Apr 09, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Epigeneres
Epigeneres has successfully raised a total of $9.83M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $1.98 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Epigeneres
Epigeneres has secured backing from 39 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include HCG, Kotak Mahindra Bank and Torrent Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel investment firm providing investment solutions
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage investments
|
Locked | Locked | Locked | |
|
Seed-stage venture capital investments are targeted by Singhvi Heritage.
|
Locked | Locked | Locked |
Investor details for Epigeneres
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epigeneres
Investment portfolio details for Epigeneres
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epigeneres
Detailed financials for Epigeneres
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epigeneres Comparisons
Peer comparison for Epigeneres
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epigeneres
Epigeneres operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Earli, Biovica and RainDance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
Tumor response to cancer therapies is monitored via specialized assays.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Volition is focused on developing epigenetic diagnostic solutions.
|
Detailed competitors of Epigeneres
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epigeneres
Complete news archive for Epigeneres
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epigeneres
Epigeneres was founded in 2008 and raised its 1st funding round 10 years after it was founded.
Epigeneres is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Epigeneres is a funded company, having raised a total of $9.83M across 3 funding rounds to date.
As of Apr 09, 2024, the latest employee count at Epigeneres is 76.
Annual revenue of Epigeneres is $419.39K as on Mar 31, 2023.
Provider of genomics based diagnostic tests for cancer. It offers HrC Test a proprietary blood-based diagnostic capable of detecting all types of cancers, including solid tumors, hematological malignancies, and soft tissue sarcomas and B (Blood-Based Biopsy) test for genetic analysis that provides deep insights into cancers presence, progression, and treatment pathways. It also offer Nutrigenomic Products such as NovaGenere and nCurcu which feature plant-based phytoextracts, antioxidants that are targeted at cellular rejuvenation, antiinflammation, and healthy aging.
Epigeneres has 39 investors. Key investors include HCG, Kotak Mahindra Bank, Torrent Pharma, LetsVenture, and Silversky Builders.
The valuation of Epigeneres is $121.84M as of Dec 2021.